Alston&Bird LLP
90 Park Avenue
New York, New York 10016
212-210-9400
Fax: 212-210-9444
www.alston.com
Mark F. McElreath | Direct Dial: 212-210-9595 | E-mail: mmcelreath@alston.com |
750 Lexington Avenue
New York, New York 10022
| | Re: | Registration Statement on Form S-3 (File No. 333-130809) |
We have acted as counsel to Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing of a registration statement (the “Registration Statement”) on Form S-3, filed on December 30, 2005, by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), and declared effective by the Commission on January 13, 2006, covering $150,000,000 in shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”). Pursuant to four Securities Purchase Agreements dated March 24, 2006, the Company issued 4,500,000 shares of Common Stock to the purchasers identified therein on March 29, 2006. This opinion letter is rendered pursuant to Item 16 of Form S-3 and Item 601(b)(5) of Regulation S-K.
We have examined the Amended and Restated Certificate of Incorporation of the Company, the Amended and Restated Bylaws of the Company, the Registration Statement, and records of proceedings of the Board of Directors, or committees thereof, deemed by us to be relevant to this opinion letter. We also have made such further legal and factual examinations and investigations as we deemed necessary for purposes of expressing the opinion set forth herein.
As to certain factual matters relevant to this opinion letter, we have relied conclusively upon originals or copies, certified or otherwise identified to our satisfaction, of such records, agreements, documents and instruments, including certificates or comparable documents of officers of the Company and of public officials, as we have deemed appropriate as a basis for the opinion hereinafter set forth. Except to the extent expressly set forth herein, we have made no independent investigations with regard to matters of fact, and, accordingly, we do not express any opinion as to matters that might have been disclosed by independent verification.
One Atlantic Center 1201 West Peachtree Street Atlanta, GA 30309-3424 404-881-7000 Fax: 404-881-7777 | Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 704-444-1000 Fax: 704-444-1111 | 3201 Beechleaf Court, Suite 600 Raleigh, NC 27604-1062 919-862-2200 Fax: 919-862-2260 | 601 Pennsylvania Avenue, N.W.North Building, 10th Floor Washington, DC 20004-2601 202-756-3300 Fax: 202-756-3333 |
Keryx Biopharmaceuticals, Inc.
March 29, 2006
Page 2
Based upon the foregoing, it is our opinion that the shares of Common Stock covered by the Registration Statement are legally issued, fully paid and nonassessable.
The opinion set forth herein is limited to the General Corporation Law of the State of Delaware, applicable provisions of the Constitution of the State of Delaware and reported judicial decisions interpreting the foregoing, and we do not express any opinion herein concerning any other laws.
This opinion letter is provided to the Company for its use solely in connection with the transactions contemplated by the Registration Statement, and may not be used, circulated, quoted or otherwise relied upon by any other person or for any other purpose without our express written consent, except that the Company may file a copy of this opinion letter with the Commission as an exhibit to a Form 8-K, as required by law. The only opinion rendered by us consists of those matters set forth in the fourth paragraph hereof, and no opinion may be implied or inferred beyond the opinion expressly stated.
| | | |
| | Sincerely, |
| | |
| | ALSTON & BIRD LLP |
|
|
|
| | By: | /s/ Mark F. McElreath |
| | Mark F. McElreath, |
| | A Partner |
